Updated:
Co-Diagnostics, Inc.
Co-Diagnostics, Inc. is listed in the Altss directory; the profile covers headquarters, registration, AUM band and key contacts for private-markets fundraising.
Overview
the Power to Know | MISSION STATEMENT
General information
Frequently asked questions
Who runs investment decisions at Co-Diagnostics, Inc.?
Co-Diagnostics, Inc. is a publicly traded company, not a family office. Investment decisions are made by its executive leadership, including the CEO and board of directors, following corporate governance rules. No single family controls the firm's investment strategy.
How does Co-Diagnostics, Inc. source its intellectual property?
The company develops its own IP through internal R&D, primarily its Co-Primer technology platform. Patents covering the Co-Primer method are held by the firm and were developed by its founding scientific team. No external licensing arrangements have been publicly disclosed as primary sources.
What investment stages does Co-Diagnostics, Inc. typically target?
Co-Diagnostics, Inc. does not make investments; it is an operating company that develops and sells diagnostic tests. The firm's capital allocation is limited to R&D spending, manufacturing capacity, and strategic partnerships for geographic expansion.
Which sectors does Co-Diagnostics, Inc. explicitly avoid?
Co-Diagnostics, Inc. focuses exclusively on molecular diagnostics for infectious diseases. It does not operate in other healthcare sectors like therapeutics, medical devices, or patient services. No public statements have been made about specific sector avoidance.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: